<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252404</url>
  </required_header>
  <id_info>
    <org_study_id>Arcothova</org_study_id>
    <nct_id>NCT04252404</nct_id>
  </id_info>
  <brief_title>FranceLEVO - Zimino Registry (FZR)</brief_title>
  <acronym>FZR</acronym>
  <official_title>FranceLEVO - Zimino® Registry: a French Registry Evaluating the Use of Levosimendan (Zimino®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcothova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcothova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The French National Authority for Health (Haute Autorité de santé) requested a registry study&#xD;
      to obtain post-market surveillance data to describe baseline clinical profiles, management&#xD;
      and outcome of patients treated with Zimino®. This study is designed to provide real-life&#xD;
      data on the use, safety and clinical outcomes of Zimino® in routine clinical practice in&#xD;
      France.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a real-life, non-interventional, observational, multicentre study in all patients&#xD;
      (including children) receiving Zimino® in France.&#xD;
&#xD;
      The patients will be evaluated during the index hospitalisation and on follow-up days 30&#xD;
      (±15) and 90 (±15) after hospital discharge. The follow-up can be a phone call or a visit to&#xD;
      the hospital. Patients who meet the eligibility criteria will be identified consecutively at&#xD;
      each hospital. The participating hospitals will vary in size and medical activities,&#xD;
      depending on their location and the population size they serve.&#xD;
&#xD;
      The physician will determine the patient's treatment strategy. Drug prescriptions and the&#xD;
      indications to perform diagnostic or therapeutic procedures will be left completely to the&#xD;
      discretion of the physicians.&#xD;
&#xD;
      The estimated enrollment period is 12 months (enrollment of the first patient - enrollment of&#xD;
      the last patient), or less if the cohort (n=600) is completed earlier, and the maximum total&#xD;
      data collection period is 15 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Actual">May 6, 2021</completion_date>
  <primary_completion_date type="Actual">January 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indication for levosimendan (Zimino)</measure>
    <time_frame>from January 28, 2020 until January 28, 2021</time_frame>
    <description>Physicians will be requested to choose one of the following indications (pop-up list):&#xD;
Cardiogenic shock (medical setting or post cardiac surgery)&#xD;
Heart failure decompensation (medical, setting)&#xD;
Low cardiac output syndrome (post cardiac surgery)&#xD;
Heart failure decompensation in a patient receiving beta-blockers&#xD;
ECMO weaning&#xD;
Repetitive use in a patient with end-stage heart failure&#xD;
Other (text)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose of levosimendan (Zimino) (in µg/kg/min)</measure>
    <time_frame>from January 28, 2020 until January 28, 2021</time_frame>
    <description>Physicians will be requested to describe the levosimendan regimen used:&#xD;
A) Loading dose (in µg/kg) B) Dose of the continuous infusion (in µg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of levosimendan (Zimino) infusion</measure>
    <time_frame>from January 28, 2020 until January 28, 2021</time_frame>
    <description>Number of hours during which the patient received levosimendan</description>
  </primary_outcome>
  <enrollment type="Actual">600</enrollment>
  <condition>Acute Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cardiac dysfunction receiving levosimendan (Zimino®)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving Zimino® treatment&#xD;
&#xD;
          -  Patients or patient's families not objecting to the patient's participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard CHOLLEY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arcothova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou, AP-HP</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arcothova</investigator_affiliation>
    <investigator_full_name>Cholley Bernard</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>low cardiac output syndrome</keyword>
  <keyword>cardiogenic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will remain with the sponsor (Arcothova)</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04252404/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04252404/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

